Cidara Therapeutics, Inc. (CDTX)

Market Cap	6.91B
Revenue (ttm)	n/a
Net Income (ttm)	-184.74M
Shares Out	31.44M
EPS (ttm)	-11.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	693,166
Open	219.90
Previous Close	219.65
Day's Range	219.51 - 219.98
52-Week Range	15.22 - 220.46
Beta	1.55
Analysts	Buy
Price Target	119.44 (-45.65%)
Earnings Date	Nov 6, 2025

About CDTX

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 15, 2015
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: CDTX
• Website: https://www.cidara.com

Financial Performance

In 2024, Cidara Therapeutics's revenue was $1.28 million, a decrease of -94.52% compared to the previous year's $23.28 million. Losses were -$169.83 million, 640.6% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price target is $119.44, which is a decrease of -45.65% from the latest price.

Price Target

$119.44

(-45.65% downside)

Analyst Consensus: Buy